News
SHINKEI Therapeutics Initiates Enrollment in Phase 2 Clinical Trial of MR-301 in Severe Traumatic Brain Injury (TBI)
PRINCETON, NJ, UNITED STATES, October 28, 2024 /EINPresswire.com/ -- SHINKEI Therapeutics, a clinical-stage pharmaceutical company dedicated to developing treatments for central nervous system (CNS) disorders, is pleased to announce that it has initi
By: kalkinemedia
- Oct 29 2024
- 0
- 0 Views
ONLY AVAILABLE IN PAID PLANS